Cargando…
Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
BACKGROUND: Exenatide once weekly (QW) is a glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment of type 2 diabetes. Safety and tolerability are key considerations in treatment selection. This analysis examines the safety and tolerability profile of exenatide QW, other approved GLP-1...
Autores principales: | MacConell, Leigh, Gurney, Kate, Malloy, Jaret, Zhou, Ming, Kolterman, Orville |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445788/ https://www.ncbi.nlm.nih.gov/pubmed/26056482 http://dx.doi.org/10.2147/DMSO.S77290 |
Ejemplares similares
-
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012) -
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
por: MacConell, Leigh, et al.
Publicado: (2012) -
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell, Leigh, et al.
Publicado: (2013) -
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
por: Blonde, Lawrence, et al.
Publicado: (2015) -
Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
por: Diamant, Michaela, et al.
Publicado: (2012)